Description
What Is Praluent 300 mg?
Praluent (alirocumab) is a fully human monoclonal antibody (IgG1) that lowers LDL cholesterol (“bad” cholesterol) in adults. It belongs to a class of medicines called PCSK9 inhibitors and is given as a subcutaneous injection. The 300 mg dose is designed as a convenient once-monthly (every 4 weeks) option for patients who prefer less frequent dosing, delivered as one 300 mg/2 mL injection from a single pre-filled pen.
Active Ingredient and Mechanism of Action
The active substance, alirocumab, targets and blocks PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein that normally binds to LDL receptors on liver cells and marks them for destruction. By inhibiting PCSK9, alirocumab allows more LDL receptors to remain available on the liver surface to clear LDL cholesterol from the blood, substantially lowering circulating LDL-C levels.
Approved Indications
- Primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet, in combination with a statin or alone/with other lipid-lowering therapies when a statin cannot be tolerated or is insufficient
- Reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease, by lowering LDL-C
Dosage and Administration
Praluent 300 mg is administered once every 4 weeks as one 2 mL subcutaneous injection from a single pre-filled pen. Other approved regimens include 75 mg every 2 weeks; the prescriber may adjust treatment according to LDL-C response and the current product information. LDL-C is commonly checked before the next scheduled monthly dose because levels can vary across the dosing interval.
How to Administer the Injection
Praluent may be self-injected after training from a healthcare professional. Before use, allow the single 300 mg/2 mL pre-filled pen to reach room temperature naturally and do not warm it by any other method. Inject subcutaneously into the thigh, abdomen, or upper arm after training from a healthcare professional, and rotate injection sites. Always follow the current package leaflet and the prescriber’s instructions.
Missed Dose
If a dose is missed, the injection should generally be administered within 7 days of the missed dose, then the patient resumes the original schedule. If more than 7 days have passed, the patient should wait until the next scheduled dose rather than doubling up. Patients should confirm the exact catch-up rule with their prescriber, as it depends on the specific dosing interval.
Overdose
There is no specific treatment for alirocumab overdose. Management is supportive: monitor the patient for any signs or symptoms of adverse reactions and provide symptomatic care as needed. Because alirocumab is a protein cleared by natural degradation, there is no antidote or dialysis-based removal. Contact emergency services or poison control for guidance in case of suspected overdose.
Storage Conditions
Store in a refrigerator (2°C–8°C) in the original carton to protect from light; do not freeze. If needed, Praluent may be kept at room temperature (up to 25°C/77°F) for a maximum of 30 days, protected from light. Do not shake the pen or syringe, and discard it if it has been frozen or exposed to temperatures above 25°C.
Contraindications
- History of a serious hypersensitivity reaction to alirocumab or any excipient in the formulation
Warnings and Precautions
Hypersensitivity reactions, including some serious events (such as hypersensitivity vasculitis and reactions requiring hospitalization), have been reported. If signs of a serious allergic reaction occur, treatment should be discontinued and appropriate therapy started. Patients should be counseled on injection technique and site rotation to minimize local reactions. Praluent is not a substitute for a heart-healthy diet and other lifestyle measures, which remain essential.
Common and Serious Side Effects
Common (may affect up to 1 in 10 people): local injection-site reactions (redness, itching, swelling, pain or tenderness), upper respiratory tract signs and symptoms (such as sore throat, runny nose, sneezing), and itching (pruritus).
Less common/serious: hypersensitivity reactions, including rare cases of hypersensitivity vasculitis and nummular eczema. Report any severe rash, swelling, or difficulty breathing to your physician immediately.
Drug Interactions
No clinically significant interactions have been identified between alirocumab and statins (such as atorvastatin or rosuvastatin); in fact, Praluent is frequently used in combination with statins for additive LDL lowering. Because alirocumab is a monoclonal antibody metabolized by general protein breakdown rather than through cytochrome P450 liver enzymes, it does not meaningfully affect the metabolism of small-molecule drugs, and standard drug-metabolism interactions are not expected.
Required Tests and Monitoring
LDL-C should be measured at baseline and reassessed within 4–8 weeks of starting or adjusting therapy, as the LDL-lowering effect is measurable within about 4 weeks. For patients on the 300 mg every-4-week regimen, LDL-C is best measured just before the next dose because levels can fluctuate across the monthly interval. Ongoing lipid monitoring guides whether the dose or interval needs adjustment.
Diet and Lifestyle Support
Praluent works best alongside a heart-healthy lifestyle. A diet low in saturated and trans fats, rich in vegetables, fruit, whole grains, legumes, and sources of soluble fiber (oats, barley, beans) supports LDL reduction. Regular physical activity, maintaining a healthy weight, limiting alcohol, and quitting smoking all further reduce cardiovascular risk. These measures complement — rather than replace — the medication’s effect.
Expected Timeline for Improvement
The LDL-lowering effect of alirocumab can be measured as early as 4 weeks after starting treatment. In clinical studies, the 300 mg every-4-week regimen produced substantial LDL-C reductions (on the order of roughly half from baseline when combined with a statin) by around week 12. Because LDL-C can vary across the monthly dosing interval, physicians assess the response using a measurement taken just before the next scheduled dose.
Effect on Other Medications and Conditions
Praluent is commonly combined with statins and other lipid-lowering agents (such as ezetimibe) without pharmacokinetic interference, allowing layered LDL reduction. It does not require dose adjustment for mild-to-moderate kidney or liver impairment, though data in severe impairment are limited. Patients with diabetes or metabolic syndrome may still use Praluent, and it does not adversely affect blood glucose control in a clinically meaningful way based on trial data.
When to See a Doctor
Seek prompt medical attention for signs of a serious allergic reaction — widespread rash, facial or throat swelling, difficulty breathing, or a severe skin reaction. Contact your physician if injection-site reactions are severe or persistent, or if you develop flu-like symptoms, joint pain, or unusual skin changes that could signal hypersensitivity vasculitis. Keep routine follow-up and lipid-testing appointments so treatment can be adjusted as needed.
Use in Special Populations
Pregnancy: data are limited; as monoclonal antibodies can cross the placenta, use during pregnancy should be based on a careful benefit-risk discussion with a physician. Breastfeeding: it is unknown whether alirocumab passes into breast milk; a decision should be made in consultation with a doctor. Renal/hepatic impairment: no dose adjustment for mild-to-moderate impairment; no data in severe impairment. Elderly: no overall difference in safety or effectiveness was observed, though greater sensitivity in some older individuals cannot be excluded.
Praluent vs Other PCSK9 Inhibitors
Praluent (alirocumab) and Repatha (evolocumab) are both PCSK9-inhibiting monoclonal antibodies used to lower LDL cholesterol and reduce cardiovascular risk. They have distinct dosing schedules and are separate molecules, though they work through the same fundamental mechanism. The choice between them, or between different dosing regimens of Praluent (300 mg monthly vs 75/150 mg every 2 weeks), is individualized by the prescribing physician based on LDL targets, tolerance, and patient preference.
Who Should Avoid Praluent
Patients with a known history of a serious hypersensitivity reaction to alirocumab or any component of the formulation should not use this medicine. As with any prescription therapy, the decision to start Praluent should follow a full review of medical history, current medications, and cardiovascular risk profile by the treating physician.
Frequently Asked Questions
Is Praluent a statin? No. Praluent is a PCSK9 inhibitor — a monoclonal antibody given by injection — which works differently from oral statins and is often used together with a statin for added LDL lowering.
Do I inject Praluent 300 mg every 2 weeks or every 4 weeks? The 300 mg dose is given once every 4 weeks as one 2 mL injection from a single pre-filled pen; an alternative approved starting regimen is 75 mg every 2 weeks, as prescribed.
Can I inject Praluent at home? Yes, after proper training from a healthcare professional, most patients self-inject at home using the pre-filled pen or syringe.
How much does it lower cholesterol? In clinical studies, meaningful LDL-C reductions were seen within weeks, with the 300 mg monthly regimen producing substantial lowering by around week 12 when combined with a statin.
Is Praluent safe long term? Cardiovascular outcomes trials evaluated alirocumab over extended periods with a generally well-tolerated safety profile; your physician monitors ongoing safety and lipid response during treatment.
Medical Review and Author Note
This content has been medically reviewed by Dr. Abdallah Fouad, Clinical Nutrition Specialist with over 25 years of experience, with reference to the current European Medicines Agency information and Praluent 300 mg/2 mL patient leaflet.
Medical Disclaimer
This information is provided for educational purposes and does not replace professional medical advice. Praluent is a prescription-only medicine and must be used strictly under the supervision of a qualified physician. Do not start, stop, or change your dose without consulting your doctor.
Praluent 300 mg Product Images
The gallery below shows the Praluent 300 mg/2 mL Alirocumab single pre-filled pen, the back and storage details, plus Arabic and English medical information cards.
Official Praluent Information
Check the European Medicines Agency Praluent page and the current Praluent 300 mg patient leaflet. Browse more health products in our online shop.
Reviews
There are no reviews yet.